Announcements Trials
Browse Landscape

Phase

Phase 2 12Phase 1/2 3Phase 3 2Phase 1 2

Status

Unknown 2Recruiting 2Not yet recruiting 2Active not recruiting 2Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Breast 1

Conditions

Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation 1Ovarian Neoplasms 1Fallopian Tube Neoplasms 1

Interventions

Cisplatin 130Radiotherapy 94Carboplatin 85Paclitaxel 78Fluorouracil 78Cyclophosphamide 77Gemcitabine 72Capecitabine 66Docetaxel 65Doxorubicin 60Oxaliplatin 59Etoposide 57Leucovorin 49Vincristine 47Chemotherapy, Adjuvant 42Cytarabine 38Dexamethasone 35Drug Therapy 33Bevacizumab 30Epirubicin 29Neoadjuvant Therapy 28Pemetrexed 27Tamoxifen 25Prednisone 24Irinotecan 24Rituximab 21Methotrexate 21Radiotherapy, Intensity-Modulated 19apatinib 18Vinorelbine 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Unknown × fluzoparib × Clear all
NCT04229615 2022-04-25

A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Unknown
690 enrolled
Gynecologic

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT04296370 2020-08-10

A Study of Fluzoparib±Apatinib Versus Chemotherapy Treatment of Physician's Choice in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Jiangsu HengRui Medicine Co., Ltd.

Phase 3 Unknown
474 enrolled
Breast

Treatment in HER2-negative Metastatic Breast Cancer Patients With Germline BRCA Mutation

Data powered by HemOnc (CC BY 4.0) Colophon âš¡